ArticleJournal of immunology research2017

Enavatuzumab, a Humanized Anti-TWEAK Receptor Monoclonal Antibody, Exerts Antitumor Activity through Attracting and Activating Innate Immune Effector Cells.

Shiming Ye et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.